Telix Pharmaceuticals Limited (TLPPF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Peers in Healthcare
Telix Pharmaceuticals Limited has no peer companies in this window.
Recent press releases
April 2026
FDA Accepts Telix's Brain Cancer Imaging Drug for Review
# 🧾 What This Document Is This is a **6-K filing**, which is how foreign companies listed on U.S. exchanges (like Telix, which is Australian) report major news to the SEC. This specific report announces a major regulatory milestone for one of their key drug candidates. # 🏢 What The Company Does �
Telix Pharmaceuticals Ltd — 6-K Filing
# 🧾 What This Document Is This is a **6-K form**, which is a report foreign companies like Telix (an Australian company listed on the US Nasdaq) file with the SEC to share major news with American investors. Think of it as a formal, required announcement to the US market. 👉 **In simple terms:** T
Telix Pharmaceuticals Ltd — 6-K Filing
# 🧾 What This Document Is This is a **Q1 2026 Quarterly Business Update** from Telix Pharmaceuticals. Think of it as a progress report for investors, showing how the company performed in the first three months of the year and what major milestones it hit. It's not an official earnings report yet (t
Telix Pharmaceuticals Ltd — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a report foreign companies like Australia's Telix Pharmaceuticals file with the U.S. SEC to keep American investors informed of major news. This specific report is an **ASX announcement** (the Australian stock exchange) detailing two key leadership
SEC filings
All filings →Insider trades
All insider trades →Telix Pharmaceuticals Limited has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Telix Pharmaceuticals Limited
All people →No officers or directors have been indexed for Telix Pharmaceuticals Limited.